Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study.

NCT00774007 is registered in ClinicalTrials.gov with SOFAR S.p.A. as lead sponsor.

NCT NCT00774007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00774007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study.
Lead sponsor
SOFAR S.p.A.
Phase
Phase 2/3
Overall status
Completed
Start date
September 30, 2004
Completion date
November 30, 2005
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome